Bournazos, S. et al. Signaling by antibodies: recent progress. Annu. Rev. Immunol. 35, 285–311 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pincetic, A. et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707–716 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leach, J. L. et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal–fetal antibody transport. J. Immunol. 157, 3317–3322 (1996).

Article  CAS  PubMed  Google Scholar 

Mallery, D. L. et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl Acad. Sci. USA 107, 19985–19990 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evers, M. et al. Novel chimerized IgA CD20 antibodies: improving neutrophil activation against CD20-positive malignancies. MAbs 12, 1795505 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Chauhan, J. et al. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4. Nat. Commun. 14, 2192 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, B. T. et al. Multimeric anti-DR5 IgM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199. Mol. Cancer Ther. 20, 2483–2494 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014). This work comprehensively reviews IgG structure, function and glycosylation.

Article  PubMed  PubMed Central  Google Scholar 

Zinn, S. et al. Advances in antibody-based therapy in oncology. Nat. Cancer 4, 165–180 (2023).

Article  PubMed  Google Scholar 

Chu, T. H., Patz, E. F. Jr. & Ackerman, M. E. Coming together at the hinges: therapeutic prospects of IgG3. MAbs 13, 1882028 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Nagelkerke, S. Q. et al. Genetic variation in low-to-medium-affinity Fcγ receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front. Immunol. 10, 2237 (2019). This thorough review examines the genetic variation in the low-affinity FcγRs and their contribution to disease in humans.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boruchov, A. M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914–2923 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910–2915 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nimmerjahn, F. et al. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41–51 (2005).

Article  CAS  PubMed  Google Scholar 

Breunis, W. B. et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111, 1029–1038 (2008).

Article  CAS  PubMed  Google Scholar 

Selvaraj, P. et al. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 333, 565–567 (1988).

Article  CAS  PubMed  Google Scholar 

Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).

Article  CAS  PubMed  Google Scholar 

Takai, T. et al. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 76, 519–529 (1994).

Article  CAS  PubMed  Google Scholar 

van Vugt, M. J. et al. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. Blood 87, 3593–3599 (1996).

Article  PubMed  Google Scholar 

Wirthmueller, U. et al. Signal transduction by FcγRIII (CD16) is mediated through the γ chain. J. Exp. Med. 175, 1381–1390 (1992).

Article  CAS  PubMed  Google Scholar 

Mitchell, M. A. et al. Substitutions and deletions in the cytoplasmic domain of the phagocytic receptor FcγRIIA: effect on receptor tyrosine phosphorylation and phagocytosis. Blood 84, 1753–1759 (1994).

Article  CAS  PubMed  Google Scholar 

Lee, J. et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salmon, J. E. et al. Fcγreceptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fcγ receptor II. J. Immunol. 146, 997–1004 (1991).

Article  CAS  PubMed  Google Scholar 

Treffers, L. W. et al. FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front. Immunol. 9, 3124 (2018).

Article  CAS  PubMed  Google Scholar 

Hunter, S. et al. Inhibition of Fcγ receptor-mediated phagocytosis by a nonphagocytic Fcγ receptor. Blood 91, 1762–1768 (1998).

Article  CAS  PubMed  Google Scholar 

Clynes, R. A. et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443–446 (2000). This seminal paper identifies the inhibitory FcγR as a negative regulator of tumour-targeting antibodies.

Article  CAS  PubMed  Google Scholar 

Simpson, A. P. et al. FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell Rep. 40, 111099 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim, S. H. et al. Fcγ receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118, 2530–2540 (2011).

Article  PubMed  Google Scholar 

Hussain, K. et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 125, 102–110 (2015).

Article  CAS  PubMed  Google Scholar 

Li, F. & Ravetch, J. V. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030–1034 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

White, A. L. et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754–1763 (2011). Together with Li and Ravetch (2011), this paper first identifies FcγRIIb as a critical mediator of agonistic antibodies against CD40.

Article  CAS  PubMed  Google Scholar 

Griffiths, J. et al. Domain binding and isotype dictate the activity of anti-human OX40 antibodies. J. Immunother. Cancer 8, e001557 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Buchan, S. L. et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity 49, 958–970.e7 (2018).

Article  CAS  PubMed  Google Scholar 

Heckel, F. et al. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun. Biol. 5, 229 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725 (2009).

Article  CAS  PubMed  Google Scholar 

Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fcγ receptors. MAbs 9, 767–773 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Unkeless, J. C. & Eisen, H. N. Binding o